Hemostats Market Size, Share, Forecast, & Trends Analysis by Type (Gelatin, Collagen, Thrombin, Fibrin, Synthetic Sealant, Gauze) Form (Sheet, Powder, Gel) Application (Orthopedic, General, Cardiovascular, Dental, Trauma) End User - Global Forecast to 2031

Hemostats Market Size & Forecast

The Hemostats Market is expected to reach $5.32 billion by 2031, at a CAGR of 6.9% from 2024 to 2031. The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. Additionally, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to offer significant market growth opportunities.

However, allergic reactions caused by the material used in making hemostats restrain the growth of this market. Additionally, the high manufacturing price for hemostats poses a significant challenge to the market's growth. Furthermore, biopolymer-based hemostats and dual-action hemostatic technology are trends prevailing in the hemostats market.

Hemostats Market Growth Drivers

Increasing Rate of Road Accidents

The rate of accidents has increased over the years. As per the U.S. Department of Health & Human Services, January 2023 report, road traffic crashes are among the leading causes of death in the U.S. Similarly, approximately 20,653 people were killed in road accidents in the EU, an increase of 3.7% compared to 2021 (Source: European Commission, Directorate-General for Communication). The increasing number of accidents has increased the number of hospital visits by patients for minor and major surgeries and wound care, driving the demand for hemostatic products in hospitals & clinics.

Click here to: Get Free Sample Pages of this Report

Growing Adoption of Minimally Invasive Surgical Procedures

The rate of minimally invasive surgeries (MIS) has been increasing in recent years. These surgeries necessitate tiny incisions, which creates demand for advanced hemostatic agents or tamponing agents to control blood loss.

With developments in minimally invasive surgery (MIS) approaches and technologies, MIS is becoming more popular in a variety of surgical disciplines, particularly cardiac surgery for coronary artery bypass surgery (CABG), valve surgery, and orthopedic surgery for hip and knee replacements. Furthermore, the adoption of minimally invasive surgeries is growing due to the benefits offered over traditional surgeries, such as easy and faster blood flow control, leading to shorter healing time and hospital stay, fewer complications, and less pain. Hemostats act as a powerful tool for surgeons to achieve hemostasis in these complicated surgeries. According to the American Society of Plastic Surgeons, in 2022, 682,932 non-invasive fat reduction surgeries and 408,970 non-invasive skin tightening surgeries were conducted in the U.S. Minimally invasive techniques frequently require operating complex cases as doctors limit the size and number of cuts or incisions. Hemostats created expressly for these procedures provide precision bleeding control, enabling surgeons to accomplish correct hemostasis.

Hemostats Market Trends

The Growing Popularity of Biopolymer-based Hemostats

Biopolymer-based hemostats are becoming popular in surgical hemostasis. These materials may assist with bleeding and come in a variety of forms, including particles, powder, sponges, sheets, foams, films, and hydrogels. Biopolymers have proven their applications as hemostatic materials due to their capabilities as biodegradable, biocompatible, and bioactive.

Biopolymer-based hemostats are meant to be biocompatible, which means the body easily absorbs them and does not trigger adverse reactions. The materials implemented in hemostats are selected with care to reduce the chance of immunological reactions and inflammation. Biopolymer-based hemostats provide a possible alternative to conventional hemostatic approaches. Their biocompatibility, absorbability, and hemostatic effectiveness make them particularly suitable choices for surgical treatments. As biopolymer technology research and development progresses, it is expected to bring more advances and higher adoption of biopolymer-based hemostats in clinical practice.

Dual-action hemostatic technology

Dual-action hemostatic technology effectively and promptly controls gingival bleeding. This technology approach ensures a comprehensive solution for managing bleeding during dental treatments. Dual-action hemostatic technology characteristics include effectivity and reliability, pose no biological risk in-vivo, are free from side effects, and stop bleeding quickly. Dual-action hemostatic technology achieves hemostasis in deep and complex wounds with secluded hemorrhagic sites. Additionally, the sealing capabilities provide suture support in vascular surgery, which is highly demanded by surgeons. Additionally, the rising preference for these hemostats is due to their dual mechanism of action, which involves the interaction of two different components which include collagen mediation of intrinsic hemostatic action liable to form fibrin clots and speedy adherence to applied tissue due to the electrophilic cross-linking with a protein-reactive polyethylene glycol monomer. Such advantages of dual-action hemostatic technology are expected to drive the hemostats market.

Hemostats Market Opportunity

The Advancements in Dental Hemostatic Agents

The use of hemostat products in dental procedures is a growing area of interest due to the advantages offered by various hemostatic agents, including gelatin-based hemostatic agents, owing to their biocompatibility, biodegradability, and low cost of raw materials. Many dental procedures, including exodontia, endosseous implantation, tissue biopsies, and periodontal surgery, have benefited due to the use of hemostats to control blood flow and its ability to reach inaccessible areas. Additionally, hemostats have been flexible to adapt to the wound and be removed easily without disintegrating into the bloodstream, owing to their increased demand in dental procedures. Furthermore, hemostats have been highly preferred by healthcare professionals to reduce increased healthcare expenditures for the patient and avoid unwanted postsurgical repair/infections associated with uncontrolled surgical bleeding. These factors have contributed to the growth of hemostats in dental procedures.

Hemostats Market Analysis: Key Findings

By Type: In 2024, the Absorbable Hemostats Segment to Dominate the Hemostats Market

Based on type, the hemostats market is segmented into absorbable hemostats and non-absorbable hemostats. In 2024, the absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostats market. The segment’s large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.

However, the non-absorbable hemostats segment is projected to witness the highest growth rate of 7.6% during the forecast period of 2022–2031. This growth is driven by the growing use of fibrin sealants as hemostats by surgeons during surgery to physically provide an effective barrier for controlling blood flow. These sealants offer high biocompatibility, less time needed for clot formation, and the use of non-absorbable hemostats in high blood flow cases.

By Application: In 2024, the Surgery Market Segment to Dominate the Hemostats Market

Based on application, the hemostats market is segmented into surgery, dental treatments, and traumatic injury. In 2024, the surgery segment is expected to account for the largest share of the hemostats market. The segment’s large share is attributed to the recurrent use of various hemostatic agents in the increasing number of orthopedic, general, gynecological, and cardiovascular surgeries, the rising number of accidents and traumatic injuries leading to surgical treatments, and the use of advanced hemostats and advance sealants by healthcare professionals in minimally invasive surgeries for controlling the blood flow.

By Form: In 2024, the Matrix and Gel Segment Dominate the Hemostats Market

Based on form, the hemostats market is segmented into sponges and dressings, sheets and pads, powder, tools, and matrix and gel. In 2024, the matrix and gel segment is expected to account for the largest share of 41.3% of the hemostats market. The segment’s large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.

This segment is also projected to witness the highest growth rate of 7.2% during the forecast period of 2022–2031.

By End User: In 2024, the Hospitals & Clinics Segment to Dominate the Hemostats Market

Based on hospitals & clinics, the hemostats market is segmented into hospitals & clinics, ambulatory surgical centers, and nursing homes. In 2024, the hospitals & clinics segment is expected to account for the largest share of the hemostats market. The significant market share of this segment is attributed to the rising number of patient visits for surgical procedures and traumatic injury treatment in hospitals, the increasing number of surgeries, the willingness to spend on advance hemostats by hospitals, and favorable reimbursement policies.

Geographical Analysis

In 2024, North America is expected to account for the largest share of 32.9% of the hemostats market, followed by Europe and Asia-Pacific. In North America, the U.S. accounted for the largest share in 2024. The significant market share of the U.S. can be attributed to several key factors including the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.

Moreover, the market in Asia-Pacific is slated to register the highest growth rate (CAGR 7.8%) due to significantly growing markets such as India and China. The growth of this market is attributed to an increase in the number of acute injuries and accidents, an increase in surgical procedures in the countries, rising medical tourism, rising healthcare expenditures, and the focus of major players in these countries due to increasing market potential.

Hemostats Market: Key Companies

The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, financial growth, and key growth strategies adopted in the last 3–4 years. Some of the key players operating in the hemostats market are Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc.(U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.). The Hemostats market is consolidated in nature, and the top 5-6 players accounted for a combined share of 40-50% in 2023.

Hemostats Market Industry Overview: Latest Developments from Key Industry Players

• In July 2023, Baxter International Inc. (U.S.) launched PERCLOT Absorbable Hemostatic Powder in the U.S. The powder is a ready-to-use product that can be used for intact coagulation in mild bleeding cases.
• In November 2023, Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson) received approval for ETHIZIA, an adjunctive hemostat solution that is proven to achieve sustained hemostasis to control excess bleeding situations.
• In July 2021, Medcura, Inc. (U.S.), in partnership with ASO, LLC (U.S.), a manufacturer of first aid products, launched an antibacterial hemostatic gel named Rapid-Seal. The gel provides antibacterial and rapid bleeding management capabilities that aid in wound treatment.
• In July 2021, Baxter International Inc. (U.S.), through its subsidiary Baxter Healthcare Corporation, acquired PerClot Polysaccharide Hemostatic System from CryoLife, Inc. (U.S.). The acquisition will strengthen Baxter’s product portfolio in hospitals, including operating rooms.
• In October 2020, Teleflex Incorporated (U.S.) will acquire privately held Z-Medica, LLC (U.S.). Z-Medica’s hemostatic technologies aid in hemorrhage control, and end users worldwide are adopting efficient bleeding control solutions.

Hemostats Market Research Summary:

Key questions answered in the hemostats market report: